On July 1, 2021 (the “Closing Date”), ICON plc, a public limited company in Ireland (“ICON”), ICON US Holdings Inc., a Delaware corporation and subsidiary of ICON (“US HoldCo”), Indigo Merger Sub Inc., a Delaware corporation and subsidiary of ICON and US HoldCo (“Merger Sub”) and PRA Health Sciences Inc., a Delaware corporation (“PRA”) completed the previously announced merger pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of February 24, 2021, by and among ICON, US HoldCo, Merger Sub and PRA. Pursuant to the terms and subject to the conditions of the Merger Agreement, Merger Sub was merged with and into PRA, with PRA surviving as a subsidiary of ICON and US HoldCo (the “Merger”). As a result of the Merger, Colin Shannon who served as PRA Chairman and Chief Executive Officer, and Linda Grais, who also served on the PRA Board, will join ICON’s Board of Directors.
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
ICON PUBLIC LIMITED COMPANY 
